Friday, June 28, 2013

Reuters: Global Markets: Dutch drugmaker Prosensa jumps 54 percent in U.S. stock market debut

Changes are afoot at Blogtrottr!
By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.
Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Dutch drugmaker Prosensa jumps 54 percent in U.S. stock market debut
Jun 28th 2013, 15:50

Fri Jun 28, 2013 11:50am EDT

(Reuters) - Dutch drugmaker Prosensa Holding received a buoyant welcome in its market debut on the Nasdaq, a day after U.S. health regulators granted a "breakthrough status" to its drug to treat a rare disease.

Prosensa's shares opened $7 above its initial public offering price of $13 and were up 46 percent at $19.05 about an hour after they started trading.

Prosensa developed drisapersen in partnership with GlaxoSmithKline Plc to treat Duchenne Muscular Dystrophy (DMD), a muscle-wasting disorder that affects one in every 3,500 newborn boys and has no available cure.

While Glaxo is responsible for most of the future development and marketing responsibilities of drisapersen, Prosensa itself has a host of ribonucleic acid-based compounds it is experimenting with to create drugs for rare genetic disorders for which there are no treatments at present.

"There is a lot of enthusiasm for Prosensa ... if a company has a strong collaboration partner and an advanced drug pipeline, they make for a good investment," said Francis Gaskins, a partner at IPO research company IPODesktop.com.

Much of Prosensa's product pipeline is aimed at treating different types of muscular dystrophies and each product has an "orphan" status in the United States and Europe -- a designation granted to drugs targeted at diseases affecting a small population.

As per the terms of a 2009 partnership agreement, Glaxo has the exclusive right to market drisapersen and options to develop various other drugs in Prosensa's portfolio.

Prosensa is eligible for up to ร‚£428 million ($650.79 million) in milestone payments from Glaxo and percentage royalties in the low tens on future global sales of drugs under the deal.

Prosensa and Glaxo are competing against Sarepta Therapeutics Inc in a race to bring the first DMD drug to market, and drisapersen, with its recently acquired "breakthrough" status, could move ahead in the regulatory review process.

Sarepta's shares were down only marginally at $38.05 after Prosensa's debut. ($1 = 0.6577 British pounds)

(Reporting by Zeba Siddiqui in Bangalore; Editing by Sreejiraj Eluvangal)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Noodles shines in Nasdaq debut, stock doubles in value

Changes are afoot at Blogtrottr!
By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.
Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Noodles shines in Nasdaq debut, stock doubles in value
Jun 28th 2013, 15:19

Fri Jun 28, 2013 11:19am EDT

(Reuters) - Shares of fast-casual restaurant chain operator Noodles & Co (NDLS.O), known for its Pad Thai and Mac & Cheese, rose 110 percent in their market debut, valuing the company at about $969 million.

The company's shares opened at $32 on the Nasdaq. Noodles raised $97.2 million by selling 5.4 million class A shares at $18 per share, above the top end of its raised price range of $15 to $17 per share.

The Broomfield, Colorado-based company owns and operates 343 restaurants, of which 52 operate under franchise arrangements, across 26 states and the District of Columbia, according to its latest filing.

Noodles shares were up 106 percent at $37.60 in late morning trading.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Home health stocks fall on proposed Medicare payment cuts

Changes are afoot at Blogtrottr!
By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.
Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Home health stocks fall on proposed Medicare payment cuts
Jun 28th 2013, 14:05

Fri Jun 28, 2013 10:05am EDT

(Reuters) - Shares of U.S. home health services providers fell on Friday after a federal agency proposed a significant cut to Medicare reimbursements payments, adding to the woes of an industry already hurt by federal budget cuts.

In a document posted on its website on Thursday, the U.S. Centers for Medicare & Medicaid Services proposed that reimbursement payments be reduced by 3.5 percent every year from 2014 to 2017. (link.reuters.com/mej39t)

Shares of Amedisys Inc (AMED.O) were down 19 percent in early trading on Friday. Shares of Gentiva Health Services Inc (GTIV.O) were down about 17 percent and those of LHC Group Inc (LHCG.O) fell 12 percent. Almost Family Inc's (AFAM.O) shares were down 8 percent.

"Last night's proposed 2014 Medicare update ... looks to be the absolute worst possible outcome for the sector," Baird Equity Research analyst Whit Mayo said in a note.

The proposed cuts come on top of a 2 percent reduction to reimbursement rates related to mandatory cuts to U.S. government spending - known as the sequestration - that went into effect earlier this year.

Mayo downgraded the home health sector to "underperform," and said all four companies were likely to lag behind market estimates for their second quarter.

"We're expecting weak volumes, coupled with the sequester, to drive second-quarter misses," Mayo said.

The companies had forecast weak 2013 profit earlier this year, citing the potential changes in reimbursement rates and the budget cuts.

(Reporting by Esha Dey in Bangalore; Editing by Anthony Kurian)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Thursday, June 27, 2013

Reuters: Global Markets: HD Supply, CDW rise in debut after pricing below expectations

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
HD Supply, CDW rise in debut after pricing below expectations
Jun 27th 2013, 17:06

Thu Jun 27, 2013 1:06pm EDT

(Reuters) - Shares of industrial supplies distributor HD Supply Holdings Inc (HDS.O) rose as much as 5.4 percent in their market debut on Thursday after they were priced well below the indicated range to attract increasingly skittish investors.

Four of the six companies that went public on Thursday were forced to either cut the price of their offering or reduce the number of shares.

HD Supply, a former division of Home Depot Inc (HD.N), was valued at about $3.53 billion at its highest trading price of $19.25. The stock was at $18.64 at midday, up 3.5 percent.

The IPO raised $957.2 million, far below the $1.33 billion that would have been raised if the shares had sold at the top end of the indicative range of $22 to $25.

Recent volatility in the equity markets has led several companies to cut the size of their IPOs or scrap them altogether.

Colony American Homes Inc, a provider of single family homes for rental, postponed its IPO earlier this month. Last week, Brazilian cement company Votorantim Cimentos postponed its $3.7 billion U.S. stock sale, citing market conditions.

Federal Reserve Chairman Ben Bernanke said last week that the Fed could wind back its stimulus policies this year if the economy continued to improve, suggesting the era of rock bottom interest rates was coming to an end.

Shares of technology products retailer CDW Corp (CDW.O), which also debuted on Thursday, rose about 9 percent in morning trading while advertising technology company Tremor Video Inc (TRMR.N) fell 5 percent.

Both companies priced below their expected offer range. CDW also reduced the number of shares offered.

Tremor's fall in its market debut does not bode well for other similar companies such as Criteo, RocketFuel and YuMe which are looking to go public later this year.

Tremor priced its 7.5 million shares at $10 per share, below the expected range of $11 to $13.

CDW, which sells products from Apple Inc (AAPL.O), Hewlett-Packard Co (HPQ.N) and others through its catalog and website, raised about $396 million after its private equity owners, Madison Dearborn LLC and Providence Equity Partners Inc, withdrew plans to sell a total of 4.5 million shares.

The two had taken CDW private in 2007 for $7.3 billion.

CDW shares were up 8.4 percent at $18.49 on the Nasdaq at midday. Tremor shares were down 3 percent at $9.70 on the New York Stock Exchange.

Smaller companies making their market debut on Thursday were Silvercrest Asset Management SAMG.O, whose shares were up 10 percent at midday, and Aratana Therapeutics (PETX.O), whose stock was up 34 percent.

(Reporting by Tanya Agrawal, Neha Dimri and Varun Aggarwal in Bangalore)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Strong motor homes demand boosts Winnebago sales

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Strong motor homes demand boosts Winnebago sales
Jun 27th 2013, 12:00

Thu Jun 27, 2013 8:00am EDT

(Reuters) - Winnebago Industries Inc (WGO.N) reported higher-than-expected quarterly revenue in the important spring selling season as rising U.S. consumer confidence pushed up demand for its recreational vehicles.

Shares of the No.1 maker of motor homes in the United States were up 6 percent at $22.20 before the bell on Thursday.

Sales of motor homes jumped 55 percent to 1,978 units in the third quarter ended June 1. Sales of towables rose 10 percent to 713 units.

"We have had exceptional growth throughout fiscal 2013, experiencing the best shipment quarter in over five years," Chief Executive Randy Potts said in a statement. (r.reuters.com/tyz29t)

U.S. consumer confidence rose to its highest level in June, supporting the Federal Reserve's view that risks to the economy have lessened.

Winnebago sells large touring vehicles and travel trailers that provide home-like comfort on the road primarily to Americans above the age of 50.

Net income rose to $7.7 million, or 27 cents per share, in the third quarter from $3.9 million, or 13 cents per share, a year earlier.

Revenue jumped 40 percent to $218.2 million.

Analysts on average expected a profit of 27 cents per share on revenue of $197.8 million, according to Thomson Reuters I/B/E/S.

Winnebago shares have more than doubled in the past 12 months, widely outperforming the 20 percent rise in the S&P 500 .SPX index.

(Reporting by Rohit Tirumala Kumara in Bangalore; Editing by Roshni Menon)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Wednesday, June 26, 2013

Reuters: Global Markets: Crown Media shares rise as unit Hallmark Cards considers taking it private

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Crown Media shares rise as unit Hallmark Cards considers taking it private
Jun 26th 2013, 16:04

Wed Jun 26, 2013 12:04pm EDT

(Reuters) - Shares of Crown Media Holdings Ltd (CRWN.O) continued to rise following a 19 percent jump on Tuesday, after its unit and largest shareholder Hallmark Cards said it was considering taking its parent private.

The greeting card company, which owns 90 percent of Crown Media, said in a filing on Monday its standstill agreement with Crown Media will expire on December 31 and Hallmark will evaluate what it can do with its investment.

A standstill agreement is often signed between lenders and borrowers to stop a lender from asking the borrower for a repayment of the loan. It may also be used to block a hostile takeover.

Hallmark Cards' options for Crown Media, which operates the Hallmark Channel, include a "going private" deal, buying more shares in Crown, urging Crown's board to initiate a stock buyback plan, or maintaining its investment in the company.

Crown and Hallmark had entered into a debt recapitalization agreement on February 26, 2010, which allowed Crown to restructure some of its $1 billion debt to Hallmark that matures on December 31, 2013.

Crown Media shares were up 6 percent at $2.63 on the Nasdaq on Wednesday. They have almost doubled in value in the last year. The company is currently valued at $892 million.

(Reporting by Chandni Doulatramani and Sayantani Ghosh in Bangalore)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Tuesday, June 25, 2013

Reuters: Global Markets: Samsung Elec shares down 3 percent on weaker earnings outlook

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Samsung Elec shares down 3 percent on weaker earnings outlook
Jun 26th 2013, 04:24

Visitors take a group photo next to a logo of Samsung Electronics Co Ltd's latest flagship smartphone S4 during its launch event at the company's headquarters in Seoul April 25, 2013.

Credit: Reuters/Kim Hong-Ji

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Large land assets help Lennar ride housing recovery wave

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Large land assets help Lennar ride housing recovery wave
Jun 25th 2013, 16:50

A Lennar model home is open for customers in a new neighborhood in the Denver suburb of Thornton, Colorado March 29, 2011. REUTERS/Rick Wilking

A Lennar model home is open for customers in a new neighborhood in the Denver suburb of Thornton, Colorado March 29, 2011.

Credit: Reuters/Rick Wilking

By Sagarika Jaisinghani

Tue Jun 25, 2013 12:50pm EDT

(Reuters) - Lennar Corp (LEN.N) reported a 27 percent rise in orders in the critical spring selling season as its large land bank helped it take advantage of a recovering U.S. housing market.

The No. 3 U.S. homebuilder's better-than-expected second-quarter results also allayed investor fears that rising mortgage rates would dampen housing demand.

"... The housing recovery is still very much intact and the fundamentals of that recovery remain solid," Chief Executive Stuart Miller said on a post-earnings conference call.

Lennar's results come on the back of strong May data, pointing to a solid housing market recovery.

The company's orders jumped to 5,705 homes in the spring selling season, which is to homebuilders what the Christmas shopping season is to retailers. Lennar booked orders for 4,481 homes in the year-ago spring quarter.

Supply of new single-family homes has been constrained as many builders cut back on buying land through the economic downturn. Builders have also complained of labor shortage, which has further slowed construction.

Lennar is better positioned than many of its peers to continue building houses as it got back into the game early and actively bought land over the past several years.

Goldman Sachs wrote in an industry note on Monday that it expects Lennar to grow faster than the national average given the company's solid land investments.

The builder, which sells homes ranging from urban infill communities to golf course communities, said on Tuesday that it had enough land to meet sales through 2014. It expects to spend about $2 billion per year on new land acquisitions from 2015.

"(Lennar's) land bank is quality land, it is adequate to meet the demand that's out there," Williams Financial Group analyst David Williams said.

U.S. homebuilder sentiment turned positive in June for the first time since the start of the housing crisis, data from the National Association of Home Builders showed.

Lennar's shares have gained almost 170 percent since the housing market started recovering in October 2011 and have outperformed the Dow Jones Home Construction Index .DJUSHB.

The stock trades at about 17 times its forward 12-month earnings SmartEstimate, according to Thomson Reuters StarMine data. Smaller peer KB Home's (KBH.N) shares trade at nearly 24 times.

Lennar shares were up 1 percent at $35.34 on Tuesday afternoon on the New York Stock Exchange.

(For a graphic on the U.S. housing market, click r.reuters.com/pum86s)

STRONG SPRING

Lennar said its average selling price rose 13 percent to $283,000 for the three months ended May.

"Affordability remains high, and despite recent interest rate increases, we have seen very little impact on sales or pricing," Miller said.

However, Williams Financial Group's David Williams said it was too early to estimate the impact of mortgage rate increases.

Interest rates started rising towards the end of May after being held at record lows by the U.S. Federal Reserve.

Lennar's backlog - houses ordered but not yet finished - rose 55 percent to 6,163 in units and 76 percent to $1.9 billion in value.

The company earned 61 cents per share on revenue of $1.43 billion for the second quarter. Analysts on average had expected earnings of 33 cents per share on revenue of $1.33 billion, according to Thomson Reuters I/B/E/S.

Lennar, the first of the top 5 U.S. homebuilders to report quarterly results, said in January it would enter the apartment rental business to take advantage of rising rents.

CEO Miller said on Tuesday that construction had begun on five apartment communities, totaling about 1,500 apartments.

(Editing by Don Sebastian and Roshni Menon)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Carnival CEO Micky Arison steps down after three decades

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Carnival CEO Micky Arison steps down after three decades
Jun 25th 2013, 17:53

By Chris Peters

Tue Jun 25, 2013 1:42pm EDT

June 25 - Cruise operator Carnival Corp's (CCL.N) chief executive of three decades, Micky Arison, will relinquish the helm next month to be replaced by a long-time board member whose last CEO job was running an artificial sweetener maker more than a decade ago.

Arnold Donald will take over running the world's largest cruise company on July 3 in the wake of a series of mishaps involving Carnival ships -- including the sinking of the Costa Concordia off Italy last year -- that have damaged its reputation and hurt bookings.

Billionaire Arison, who owns about 30 percent of the company his father Ted co-founded in 1972, will remain chairman.

Shares of Carnival, which also reported stronger-than-expected earnings on Tuesday, rose as much as 5 percent on Tuesday. However, the company said bookings and prices for the rest of the year were lower than last year.

Carnival's shares had fallen about 15 percent since February when another ship, Carnival Triumph, was left adrift in the Gulf of Mexico for several days following an engine fire.

"It's good to separate the CEO and chairman roles. It helps with checks and balances," Morningstar analyst Jamie Katz said.

Arison, who just celebrated a second NBA title as owner of the Miami Heat, was criticized earlier this year for attending a game while passengers were drifting on the Triumph.

"I'm going to be looking to Arnold to run the day-to-day corporate operations and I may even take a couple of golf lessons," Arison, 63, said on an analyst call when asked how involved he would remain in the company's operations.

Still, the new CEO remains a largely unknown quantity.

"On one hand Donald is a good choice in terms of someone that has familiarity with the company, on the other hand he doesn't necessarily have the direct operational experience," ITG analyst Matthew Jacob said.

Donald, who has been on the Carnival board for 12 years, was senior vice-president at Monsanto (MON.N) in the late 90s and served as chief executive of the seed giant's Equal sweetener business, when it was spun off as Merisant Co in 2000.

Since then, he has primarily served as a director of several companies, including Bank of America Corp (BAC.N).

RECOVERY BEGINS?

Carnival, which owns the Carnival, Holland America, P&O, and Cunard cruise lines, among others, also reported a quarterly profit that beat analyst estimates, helped by lower fuel prices.

Fuel prices decreased 9.7 percent to an average $683 per metric ton from a year earlier.

"Our advisers are saying that the recovery will be gradual and it will take two to three years for the Carnival brand to fully recover, but the good news is that it appears that the recovery has started," Chief Operating Officer Howard Frank said on the call.

The company, which has cut its full-year profit outlook twice this year, reaffirmed its forecast of earnings of $1.45 to $1.65 per share. Analysts on average were expecting $1.60 per share, according to Thomson Reuters I/B/E/S.

Carnival's net income rose to $41 million, or 5 cents per share, in the second quarter from $14 million, or 2 cents per share, a year earlier. Excluding items, the company earned 9 cents per share. Revenue fell 2 percent to $3.48 billion.

Analysts had forecast quarterly earnings of 6 cents per share on revenue of $3.55 billion.

Carnival's shares were up 4.7 percent at $34.74 on the New York Stock Exchange at midday. Shares of its main rival, Royal Caribbean Cruises Ltd (RCL.N), were up 4 percent at $33.08.

(Reporting by Chris Peters in Bangalore and Phil Wahba in New York; Editing by Roshni Menon and Ted Kerr)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Demand Media's shares lose 20 percent on concerns of Google reliance

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Demand Media's shares lose 20 percent on concerns of Google reliance
Jun 25th 2013, 14:29

Tue Jun 25, 2013 10:29am EDT

(Reuters) - Shares of Demand Media Inc (DMD.N) plunged 20 percent in Tuesday morning trading after the company trimmed its second-quarter revenue forecast and withdrew its 2013 estimates, prompting two researchers to downgrade the company's stock.

Demand Media on Monday lowered its second-quarter forecast, blaming a reduction in search engine referral traffic and it announced the acquisition of an e-commerce platform Society6.

Demand Media, which owns websites eHow, Livestrong and Cracked, has been dogged in recent years by the changes Google (GOOG.O) made to its search engine algorithm. It depends on high search results for its content for advertising revenue.

Demand relies heavily on Google for traffic. About 40 percent of its first-quarter revenue was derived from advertising agreements with Google.

"Google's algorithm change is having a greater impact than previously expected," wrote Stifel, Nicolaus analyst Jordan Rohan, who downgraded the stock to "hold" from "buy." "Demand is again at the mercy of Google's indexing."

Demand Media is actively shifting its business model toward subscription and e-commerce revenue and said it plans to spin out its registrar business.

"Unfortunately, these positives may be overwhelmed in the near term by the traffic issues with Google," wrote Patrick Walravens, an analyst with JMP Securities, which downgraded the stock to "market perform," from "market outperform."

Shares of Demand Media were down 24 percent at $6.23 in morning trading.

(Reporting by Jennifer Saba in New York; Editing by Maureen Bavdek)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Barnes & Noble says Nook, retail sales plunge, more pain coming

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Barnes & Noble says Nook, retail sales plunge, more pain coming
Jun 25th 2013, 13:23

  • Tweet
  • Share this
  • Email
  • Print
People walk past a Barnes and Noble store in New York October 24, 2012. REUTERS/Brendan McDermid

People walk past a Barnes and Noble store in New York October 24, 2012.

Credit: Reuters/Brendan McDermid

By Phil Wahba

Tue Jun 25, 2013 9:23am EDT

(Reuters) - Barnes & Noble Inc (BKS.N) reported on Tuesday that its quarterly net loss more than doubled as sales of its Nook device and e-books continued to plunge, and it forecast a sharp drop in business at its bookstores.

Shares were down 7.5 percent at $17.40 in premarket trading.

Revenue of its Nook business, including e-books and devices, fell 34 percent as it sold fewer e-readers and tablets and slashed prices.

Barnes & Noble, the largest U.S. bookstore chain, launched the first version of the Nook e-reader in 2009 to take on Amazon.com Inc's (AMZN.O) market-leading Kindle and secure a place in the fast growing e-books market. It now also competes with devices by Apple Inc (AAPL.O) and Google Inc (GOOG.O).

But fighting such deep pocketed rivals has been expensive: Barnes & Noble lost $475.4 million last fiscal year and it had to repeatedly cut prices to try to attract shoppers.

To contain those losses, Barnes & Noble said its tablets will now be produced and marketed in partnership with a consumer electronics manufacturer it did not identify. It will continue to develop its e-readers itself.

The picture was also bleak in its retail business, consisting of its 675 bookstores and accounting for two-thirds of sales. Sales at stores open at least 15 months fell 8.8 percent last quarter. Barnes & Noble expects retail sales to be down by a high single digit percentage in its new fiscal year.

Earlier this year, Leonard Riggio, the company's chairman, founder and largest shareholder, said he wanted to buy Barnes & Noble's bookstores chain.

One bright spot was its college bookstore chain, where same-store sales rose 7.5 percent. Still, Barnes & Noble forecast a low-single digit percentage decline for fiscal 2014.

Company wide, revenue was down 7.4 percent to $1.28 billion.

The retailer reported a net loss of $118.6 million, or $2.11 per share, for the fiscal fourth quarter ended April 27, compared with a loss of $56.9 million, or $1.06 per share, a year earlier.

(Reporting by Phil Wahba in New York; Editing by Gerald E. McCormick and Chris Reese)

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Monday, June 24, 2013

Reuters: Global Markets: FDA draft guidance on generic eye drug push Allergen shares lower

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
FDA draft guidance on generic eye drug push Allergen shares lower
Jun 24th 2013, 20:35

By Toni Clarke

WASHINGTON | Mon Jun 24, 2013 4:35pm EDT

WASHINGTON (Reuters) - Shares of Allergan Inc (AGN.N) fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly.

In a move that surprised investors, the U.S. Food and Drug Administration proposed allowing companies to apply for marketing approval of generic versions of Restasis based on laboratory tests, not on human clinical trials.

The FDA said in its proposed guidance that conducting a study in humans to test whether the drugs are essentially equivalent would not be feasible or reliable due to the "modest efficacy" of Restasis.

Analysts said the draft guidance, if adopted following a 60-day period of public comment, makes the arrival of a generic version of Restasis much more likely. The patent on Restasis expires in May 2014.

"Today's draft guidance suggests the FDA is conceptually open to the idea of granting approval to a generic without running a study," said Chris Schott, an analyst at J.P. Morgan in a research note. "We see today's update from the FDA as introducing incremental risk to one of Allergan's key franchises."

Allergan expects Restasis, which was approved in the United States in 2002, to generate sales of $850-$890 million in 2013, or as much as 15 percent of its total sales. The product, also known as cyclosporine ophthalmic emulsion, is designed to improve the eye's natural ability to produce tears.

Allergan said in a statement it believes the FDA's proposed testing method "cannot predict clinical safety and efficacy, and thus cannot be used to establish bioequivalence."

The company said it will provide this feedback to the FDA during the public comment period and added that it is reviewing all its potential options, including filing a Citizen's Petition "to ensure that the appropriate scientific considerations are evaluated."

Even if the guidance is adopted, however, some analysts say the likelihood of a generic version of Restasis being introduced immediately following the expiration of its patent to be low, in part due to the drug's complex manufacturing process.

"We believe that the exact timing of such an event is uncertain and, at this time, see a low probability of generic competition immediately following the May 2014 patent expiration," said Larry Biegelsen, an analyst at Wells Fargo Securities, in a research note.

Biegelsen expects sales of Restasis to rise to more than $1 billion beginning in 2015.

The FDA also offered generic companies the option of conducting a human clinical trial, but said if they choose that route they should first submit the trial's protocol to the agency for review.

Allergan's shares closed down 11.6 percent at $81.99.

(Reporting by Toni Clarke in Washington; Additional reporting by Ransdell Pierson in New York)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Isis shares jump after experimental drug cuts blood fat

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Isis shares jump after experimental drug cuts blood fat
Jun 24th 2013, 15:29

Mon Jun 24, 2013 11:29am EDT

(Reuters) - Shares of Isis Pharmaceuticals Inc (ISIS.O) rose as much as 24 percent after the drugmaker said its experimental drug reduced triglycerides, a type of fat, in blood and increased the level of "good" cholesterol.

The results were "well beyond expectations and suggest an unprecedented treatment benefit in type 2 diabetics with (high cholesterol levels)," BMO Capital Markets analyst Jim Birchenough said.

"A blockbuster opportunity could emerge," said Birchenough, who forecast the drug's peak sales at about $850 million, if approved.

Isis said on Sunday that its drug cut patients' triglyceride levels by 72 percent and increased high-density lipoprotein cholesterol, or "good cholesterol," levels by 40 percent.

The study, the first of three mid-stage studies, comprised 11 patients and was conducted for 13 weeks.

Needham & Co analyst Chad Messer, who has a "buy" rating on the stock with a target price of $29, said the program is "one of the more significant of many potential drivers for Isis shareholders over the next 12-18 months."

Birchenough has an "outperform" rating on the company's stock with a target price of $31.

Isis shares were up 22 percent at $26.89 on the Nasdaq after touching a 13-year-high of $27.34 on Monday morning.

The U.S. Food and Drug Administration approved Isis' and Sanofi SA's (SASY.PA) Kynamro which targets a rare genetic disorder that causes dangerously high levels of bad cholesterol.

The company has several drug candidates in clinical development in cardiovascular, inflammatory, cancer and other areas. All the drugs are based on Isis' antisense technology รข€" which seeks to prevent the production of proteins involved in the disease.

(Reporting by Pallavi Ail in Bangalore; Editing by Joyjeet Das)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Pfizer says shareholders snap up remaining Zoetis shares

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Pfizer says shareholders snap up remaining Zoetis shares
Jun 24th 2013, 13:38

  • Tweet
  • Share this
  • Email
  • Print
A woman walks past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid

A woman walks past the Pfizer Inc. headquarters in New York, January 31, 2013.

Credit: Reuters/Brendan McDermid

Mon Jun 24, 2013 9:38am EDT

(Reuters) - Pfizer Inc (PFE.N) said on Monday that enough Pfizer shareholders offered to trade their shares for stock in Pfizer's majority owned Zoetis Inc (ZTS.N) animal health business to allow Pfizer to complete its spinoff of the unit.

Pfizer said all its Class A Zoetis common stock will be distributed to Pfizer shareholders who validly tendered required shares of Pfizer stock, and as a result Pfizer no longer will hold any ownership interest in Zoetis.

The drugmaker said it continues to expect the separation of Zoetis to boost Pfizer's earnings in 2014.

(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick)

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Sunday, June 23, 2013

Reuters: Global Markets: Con-Way shares to rise after business overhaul: Barron's

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Con-Way shares to rise after business overhaul: Barron's
Jun 23rd 2013, 23:02

Sun Jun 23, 2013 7:02pm EDT

(Reuters) - Shares of Con-Way Inc (CNW.N) could jump by as much as 20 percent by year-end after the U.S. trucking company finishes overhauling its business as the country's economy recovers, business weekly Barron's said in its June 24 edition.

The company has suffered for several years as the economy stalled, leading to price wars between trucking companies competing for a falling volume of freight traffic.

Barron's said Con-Way's profit margins had dropped to 2 percent in the first quarter of this year from 9.5 percent in 2006 and that the company's market share has been languishing at 10 percent for years.

"Investors shouldn't despair," Barron's wrote.

"Con-Way is about halfway through a costly, three-year overhaul of its operations that should pay off in improved earnings and a share price that could rise this year as much as 20 percent above last week's $39," the paper said.

The overhaul involves a "lean" approach to the business, created by Japanese carmaker Toyota (7203.T), that saves costs through cutting processes, shifting decision making to the frontline, introducing a new pricing mechanism and a new logistical system.

Analysts have noticed the changes at Con-Way, but Barron's said if the changes are not implemented successfully, heads could roll.

(Reporting by Sabina Zawadzki, editing by G Crosse)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

 
Great HTML Templates from easytemplates.com.